Sylvest Advisors LLC Acquires Shares of 13,769 Bristol Myers Squibb Company $BMY

Sylvest Advisors LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 13,769 shares of the biopharmaceutical company’s stock, valued at approximately $835,000. Bristol Myers Squibb makes up about 0.4% of Sylvest Advisors LLC’s portfolio, making the stock its 26th biggest holding.

A number of other large investors also recently added to or reduced their stakes in the stock. Northwestern Mutual Investment Management Company LLC increased its stake in shares of Bristol Myers Squibb by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after purchasing an additional 172 shares in the last quarter. KCM Investment Advisors LLC raised its position in shares of Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 174 shares during the last quarter. Investment Research Partners LLC lifted its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 179 shares in the last quarter. ESG Planning DBA Harper Investing boosted its holdings in Bristol Myers Squibb by 1.3% in the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after buying an additional 180 shares during the last quarter. Finally, REAP Financial Group LLC increased its stake in Bristol Myers Squibb by 26.1% during the 4th quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 182 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $57.45 on Friday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The firm has a market capitalization of $117.31 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The business’s fifty day moving average price is $57.06 and its 200 day moving average price is $57.27.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Bank of America dropped their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Finally, Guggenheim reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.